Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11877MR)

This product GTTS-WQ11877MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11877MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11967MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ11149MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ13047MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ14468MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ4240MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ4850MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ5735MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10156MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LBR-101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW